Is it acceptable to treat patients with limited, asymptomatic brain metastases and EGFR-mutant NSCLC with upfront TKI?  

Can SRS or whole brain radiotherapy be reserved for progression in these young, healthy patients?



Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Community Practice

Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Community Practice

Answer from: Radiation Oncologist at Community Practice

Answer from: Radiation Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice

Answer from: Radiation Oncologist at Community Practice